In one paragraphArticle in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Luana Leandro GoisDepartamento de Biointeração, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador 40231-300, Bahia, Brazil.ORCID 0000-0002-7538-3558 Natália Barbosa CarvalhoServiço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador 40110-060, Bahia, Brazil.ORCID 0000-0003-2586-7877 Fred Luciano Neves SantosLaboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.ORCID 0000-0002-3944-0818 Carlos Gustavo Regis-SilvaLaboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.
Thainá Gonçalves Tolentino FigueiredoEscola Bahiana de Medicina e Saúde Pública, Salvador 40290-000, Bahia, Brazil.
Bernardo Galvão-CastroLaboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.
Edgar Marcelino CarvalhoServiço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador 40110-060, Bahia, Brazil.ORCID 0000-0002-2697-8002 Maria Fernanda Rios GrassiLaboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.ORCID 0000-0002-7356-5569 Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior financial code 001Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB) 1637/2011, Edital 028/2010 and INC0003/2019Fundação Nacional de Desenvolvimento do Ensino Superior Particular 9600140 and 9600141National Council for Scientific and Technological Development 308167/2021-0 and 473667/2012-6
6 · The paper itselfAbstract
Human T-cell leukemia virus type 1 (HTLV-1) is associated with an increased risk of tuberculosis (TB). This study aimed to evaluate the performance of the QuantiFERON-TB Gold (QFT) test for the diagnosis of
Indexed as
HTLV-I InfectionsHuman T-lymphotropic virus 1Interferon-gamma Release TestsMycobacterium tuberculosisSensitivity and SpecificityTuberculosisAdultAgedCoinfectionFemaleHumansMaleMiddle AgedTuberculin TestHTLV-1QuantiFERONtuberculin skin testtuberculosis
Identifiers
PMID39772183
PMCPMC11680234
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390